Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review
In order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.
Using Extracorporeal Photopheresis in the Treatment of Graft-Versus-Host Disease
Extracorporeal photopheresis takes approximately 3 to 4 hours to complete and involves leukapheresis, separation of the buffy coat, photoactivation, and finally reinfusion.
Deciphering the Challenge of the Genomic Era in Breast Cancer
Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate
Rethinking Initial Management of Patients With Brain Metastasis and HER2 Breast Cancer
Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512